Glaukos Epioxa shows lasting vision benefits three years after single keratoconus treatment
Glaukos Corporation reported that patients treated with its Epioxa corneal cross-linking therapy maintained improvements in vision and corneal shape three years after a single treatment for keratoconus, a progressive eye disease that distorts vision. The three-year extension study demonstrated sustained clinical outcomes and a favorable long-term safety profile.
